HLB Life Science Co. Ltd (067630) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.016x

Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.30 Billion ≈ $-2.92 Million USD) by net assets (₩277.26 Billion ≈ $187.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 067630 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

HLB Life Science Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how HLB Life Science Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

HLB Life Science Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Life Science Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Stomil Sanok SA WAR:SNK	0.074x
Hwashin Precision Engineering Co. Ltd KQ:126640	-0.060x
SR Bancorp, Inc. Common stock NASDAQ:SRBK	0.019x
P2 Gold Inc V:PGLD	-0.511x
Soechi Lines Tbk JK:SOCI	0.031x
Hardwyn India Limited NSE:HARDWYN	0.001x
Thessaloniki Water Supply & Sewerage Co S.A AT:EYAPS	0.000x
Korea Information Certificate Authority Inc KQ:053300	0.019x

Annual Cash Flow Conversion Efficiency for HLB Life Science Co. Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of HLB Life Science Co. Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of HLB Life Science Co. Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩398.83 Billion ≈ $270.28 Million	₩-32.01 Billion ≈ $-21.69 Million	-0.080x	-85.25%
2023-12-31	₩231.21 Billion ≈ $156.69 Million	₩-10.02 Billion ≈ $-6.79 Million	-0.043x	+65.81%
2022-12-31	₩234.72 Billion ≈ $159.07 Million	₩-29.74 Billion ≈ $-20.16 Million	-0.127x	-121.50%
2021-12-31	₩246.19 Billion ≈ $166.84 Million	₩-14.08 Billion ≈ $-9.54 Million	-0.057x	-917.36%
2020-12-31	₩287.18 Billion ≈ $194.62 Million	₩2.01 Billion ≈ $1.36 Million	0.007x	+118.86%
2019-12-31	₩333.82 Billion ≈ $226.23 Million	₩-12.39 Billion ≈ $-8.39 Million	-0.037x	+26.58%
2018-12-31	₩219.09 Billion ≈ $148.47 Million	₩-11.07 Billion ≈ $-7.50 Million	-0.051x	-783.95%
2017-12-31	₩52.83 Billion ≈ $35.80 Million	₩-302.04 Million ≈ $-204.69K	-0.006x	+93.04%
2016-12-31	₩27.68 Billion ≈ $18.76 Million	₩-2.27 Billion ≈ $-1.54 Million	-0.082x	+51.02%
2015-12-31	₩25.90 Billion ≈ $17.55 Million	₩-4.34 Billion ≈ $-2.94 Million	-0.168x	-121.60%
2014-12-31	₩13.44 Billion ≈ $9.11 Million	₩10.43 Billion ≈ $7.07 Million	0.776x	+190.44%
2013-12-31	₩11.03 Billion ≈ $7.48 Million	₩2.95 Billion ≈ $2.00 Million	0.267x	-86.53%
2012-12-31	₩7.04 Billion ≈ $4.77 Million	₩13.97 Billion ≈ $9.47 Million	1.984x	--

About HLB Life Science Co. Ltd

KQ:067630 Korea Pharmaceuticals

Market Cap

$136.50 Million

₩201.42 Billion KRW

Market Cap Rank

#18086 Global

#802 in Korea

Share Price

₩4300.00

Change (1 day)

+0.70%

52-Week Range

₩3235.00 - ₩5750.00

All Time High

₩23674.87